Interviews

Dr. Walker, an interventional cardiologist with Cardiovascular Institute of the South and a clinical professor of medicine at Tulane University and LSU medical schools, served as an EXCITE ISR co-principal investigator. Vascular Disease...

In April, the first training center for vascular clinical trials opened in Boston.

At the 2014 VEITH symposium, Michel S. Makaroun, MD, presented data on his case experience along with clinical trial updates for Gore’s new thoracic and iliac branch stent grafts.

At the 2014 VEITHsymposium, Vascular Disease Management spoke with Mark F. Fillinger, MD, about 2-year results of the Aorfix PYTHAGORAS trial, for which he served as principal investigator. 

Peter Schneider, MD, describes results from the European and US arms of the IN.PACT SFA trial, which evaluated safety and efficacy of the In.Pact Admiral drug-eluting balloon compared to plain balloon angioplasty in the superficial femoral...

The multicenter randomized controlled IN.PACT DEEP trial compared paclitaxel-coated balloons with uncoated balloons and failed to show benefit for the drug-eluting balloon.

Dr. Andrej Schmidt, MD, senior interventionalist at the University Clinic of Leipzig in Germany, discusses results from a single-center study using paclitaxel-coated drug-eluting balloons for infrapopliteal lesions. 

Jeffrey Lawson, MD, of Duke University, discusses engineering of an implantable blood vessel from donor vascular cells. The technology has received US Food and Drug Administration fast-track designation for approval, and clinical trials are...

At the 41st annual VEITHSymposium, Erik E. Debing, MD, PhD, presented mid-term results from the Belgian IN.PACT trial. Vascular Disease Management asked Dr. Debing to share details about the results.

Vascular Disease Management spoke about the BIOLUX P-III study with clinical investigator Gunnar Tepe, MD, head of the Institute of Diagnostic and Interventional Radiology at RoMed Clinic Rosenheim in Germany.